MCID: CMM003
MIFTS: 34

Common Wart

Categories: Infectious diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Common Wart

MalaCards integrated aliases for Common Wart:

Name: Common Wart 11 14 16 71
Verruca Vulgaris 33
Viral Warts Nos 33
Filiform Warts 33
Digitate Warts 33

Classifications:



External Ids:

Disease Ontology 11 DOID:11165
NCIt 49 C5028
SNOMED-CT 68 30285000
UMLS 71 C0043037

Summaries for Common Wart

Disease Ontology: 11 A viral infectious disease that results in infection located in skin, has material basis in human papillomavirus (types 2 and 4). This infection is characterized by a raised wart with roughened surface, most common on hands, but can grow anywhere on the body.

MalaCards based summary: Common Wart, also known as verruca vulgaris, is related to plantar wart and keratosis, seborrheic. An important gene associated with Common Wart is MIR1914 (MicroRNA 1914), and among its related pathways/superpathways is BARD1 signaling events. The drugs Cantharidin and Copper have been mentioned in the context of this disorder. Affiliated tissues include skin, tongue and nk cells.

Related Diseases for Common Wart

Diseases related to Common Wart via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 174)
# Related Disease Score Top Affiliating Genes
1 plantar wart 30.6 TMC8 TMC6
2 keratosis, seborrheic 30.3 TP53 TMC8 TMC6
3 acanthoma 30.2 TP53 TMC8 TMC6
4 focal epithelial hyperplasia 30.0 TP53 TMC8 TMC6
5 superficial basal cell carcinoma 29.7 TLR7 IFNA1 CD4
6 anogenital venereal wart 29.5 TP53 TMC8 TLR7 IFNA1 CD4
7 chickenpox 29.5 IFNA1 DOCK8 CD4
8 skin carcinoma 29.3 TP53 TMC8 TMC6 TLR7 CD4
9 epidermodysplasia verruciformis 1 29.2 TP53 TMC8 TMC6 DOCK8 CD4 CCDC39
10 clear cell acanthoma 11.2
11 papilloma 10.6
12 viral infectious disease 10.4
13 keratosis 10.4
14 basal cell carcinoma 1 10.3
15 basal cell carcinoma 10.3
16 angiokeratoma of fordyce 10.3 TMC8 TMC6
17 pityriasis versicolor 10.2 TMC8 TMC6
18 molluscum contagiosum 10.2
19 dendritic cell thymoma 10.2 PCNA CD4
20 dilution, pigmentary 10.1
21 vitiligo-associated multiple autoimmune disease susceptibility 6 10.1
22 leprosy 3 10.1
23 vitiligo-associated multiple autoimmune disease susceptibility 1 10.1
24 lepromatous leprosy 10.1
25 squamous cell carcinoma 10.1
26 dermatitis 10.1
27 keratoacanthoma 10.1
28 skin squamous cell carcinoma 10.1
29 epidermolytic acanthoma 10.1
30 syringocystadenoma papilliferum 10.1
31 inverted follicular keratosis 10.1
32 superficial mycosis 10.1 TMC8 TMC6 CD4
33 suppurative lymphadenitis 10.1 DOCK8 CD4
34 blepharoconjunctivitis 10.1 DOCK8 CD4
35 fibrillary astrocytoma 10.1 TP53 PCNA
36 mastoiditis 10.1 DOCK8 CD4
37 whim syndrome 1 10.1 TMC8 TMC6 DOCK8
38 external ear disease 10.1 DOCK8 CD4
39 lung abscess 10.1 DOCK8 CD4
40 subcutaneous mycosis 10.0 TLR7 CD4
41 otitis externa 10.0 DOCK8 CD4
42 skin tag 10.0
43 immune-complex glomerulonephritis 10.0 TLR7 CD4
44 immunodeficiency 14 10.0 DOCK8 CD4
45 anal squamous cell carcinoma 10.0 TP53 CD4
46 immunodeficiency 41 with lymphoproliferation and autoimmunity 10.0 DOCK8 CD4
47 acanthosis nigricans 10.0
48 epidermolytic hyperkeratosis 10.0
49 darier-white disease 10.0
50 lentigines 10.0

Graphical network of the top 20 diseases related to Common Wart:



Diseases related to Common Wart

Symptoms & Phenotypes for Common Wart

Drugs & Therapeutics for Common Wart

Drugs for Common Wart (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cantharidin Approved, Investigational Phase 4 56-25-7 2545
2
Copper Approved, Investigational Phase 4 7440-50-8 27099
3 Vaccines Phase 4
4 Copper Supplement Phase 4
5
Ethanol Approved Phase 3 64-17-5 702
6
Hydrogen peroxide Approved, Vet_approved Phase 3 7722-84-1 784
7
Povidone-iodine Approved Phase 2 25655-41-8
8
Iodine Approved, Investigational Phase 2 7553-56-2 807
9
Povidone K30 Approved, Experimental, Withdrawn Phase 2 9003-39-8 6917 131751496
10
Cadexomer iodine Experimental Phase 2 94820-09-4
11 Anti-Infective Agents Phase 2
12 Anti-Infective Agents, Local Phase 2
13 Blood Substitutes Phase 2
14 Plasma Substitutes Phase 2
15
Aminolevulinic acid Approved 106-60-5 137
16
Methylene blue Approved, Investigational 61-73-4 6099
17
Cholecalciferol Approved, Nutraceutical, Vet_approved 67-97-0, 1406-16-2 5280795 10883523
18 Vitamins
19 Trace Elements
20 Calciferol
21 Hormones
22 Calcium, Dietary
23 Micronutrients
24 Pharmaceutical Solutions
25 Immunologic Factors
26 Immunoglobulins, Intravenous
27 Immunoglobulins
28 Antibodies, Monoclonal
29 Antibodies
30
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts : a Randomized Controlled Trial Completed NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
2 Study to Evaluate the Efficacy of 2LVERU® JUNIOR and 2LVERU® on the Treatment of Warts. Recruiting NCT03977753 Phase 4 2LVERU® or 2LVERU® JUNIOR;Placebo
3 Using a Cold Atmospheric Plasma Device to Treat Molluscum Contagiosum and Verruca Vulgaris in Pediatric Patients Recruiting NCT05070754 Phase 4 Canthardin Collodion
4 Efficacy of Cryotherapy Combined With Intralesional Tuberculin Purified Protein Derivative (PPD) Versus Interlesional Tuberculin PPD Monotherapy in the Treatment of Multiple Common Warts Unknown status NCT04288817 Phase 3
5 A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts Completed NCT03691831 Phase 3 Active
6 A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts Completed NCT03687372 Phase 3 A-101
7 A Phase 3 Open Label Safety Study of A-101 Topical Solution for the Treatment of Common Warts Completed NCT03812510 Phase 3 A-101
8 A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years Unknown status NCT02640820 Phase 2 Sensitizing DPCP Ointment;Treatment DPCP Ointment
9 A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts Completed NCT03278028 Phase 2 A-101 Topical Solution;A-101 Vehicle Solution
10 A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Once a Week in Subjects With Common Warts Completed NCT03210337 Phase 2 A-101 Topical Solution;A-101 Vehicle Solution
11 A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects With Common Warts (Verruca Vulgaris) Completed NCT03487549 Phase 2
12 A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris) Completed NCT02393417 Phase 2
13 ALC-919 For The Treatment Of Common Warts (Verruca Vulgaris) Completed NCT02483455 Phase 2 2014-ALC-919-US;Vehicle-Control Topical Solution
14 A Randomized, Double-blind, Multi-center, Placebo-controlled, Dose-ranging, Efficacy and Safety Trial of a New Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) for Treatment of Common Warts (Verruca Vulgaris) Completed NCT01286441 Phase 2 10% EISO;Placebo;20% EISO;30% EISO
15 A Phase 2, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Study to Evaluate Topical 2% Povidone-Iodine Gel (VBP-245) in Subjects With Verruca Vulgaris Active, not recruiting NCT04253912 Phase 2 VBP-245;Placebo Gel (no Povidone-Iodine)
16 A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients. Suspended NCT01796795 Phase 2 Vehicle gel;SR-T100 gel with 1.0% of SM;SR-T100 gel with 2.3% of SM
17 An Open Label Exploratory Study Evaluating the Efficacy and Safety of Ingenol Mebutate 0.05% Gel for the Treatment of Verruca Vulgaris. Completed NCT02748902 Phase 1 ingenol mebutate 0.05% gel
18 A Phase I, Single-Centre, Open-Label, Fixed-Dose Study of the Safety and Efficacy of up- to Three-Days Application of 0.05% PEP005 Topical Gel in the Treatment of Patients With Common Wart(s) (Verruca[e] Vulgaris) on the Dorsal Hand Withdrawn NCT00546611 Phase 1 PEP005
19 Topical 5-Aminolevulinic Acid Photodynamic Therapy for the Treatment of Verruca Vulgaris: Comparison of Red and Green Light-Emitting Diode Array Unknown status NCT00155584
20 Double-Blind, Randomized Control Trial To Evaluate the Efficacy of Duct Tape Versus Placebo for the Treatment of Verruca Vulgaris Completed NCT00328991
21 A Randomized Clinical Trial Examining the Efficacy of Treatment of Cutaneous Verruca Vulgaris in Adult Patients With Combined Liquid Nitrogen Cryotherapy and Topically Applied Cantharidin Completed NCT01084824 Liquid nitrogen and cantharidin;Liquid nitrogen and topical placebo
22 Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study Completed NCT04793529 Cholecalciferol
23 Prospective, Open Clinical Investigation to Evaluate the Effectiveness and Safety of Wortie® Freeze Plus in the Treatment of Common Warts and Plantar Warts Recruiting NCT05115669
24 Assessment of Squamous Cell Carcinoma antigen2 in Verruca Vulgaris Recruiting NCT05409365
25 PHOTODYNAMIC THERAPY USING METHYLENE BLUE AND INTENSE PULSED LIGHT VERSUS INTENSE PULSED LIGHT ALONE IN TREATMENT OF VERRUCA :A RANDOMIZED CONTROLLED STUDY Recruiting NCT04620785
26 Randomized Double Blind Study Comparing Liquid Nitrogen Cryotherapy With Nd:YAG in the Treatment of Verruca Vulgaris Terminated NCT01609530

Search NIH Clinical Center for Common Wart

Genetic Tests for Common Wart

Anatomical Context for Common Wart

Organs/tissues related to Common Wart:

FMA: Skin
MalaCards : Skin, Tongue, Nk Cells, Bone Marrow, Bone, Kidney, Breast

Publications for Common Wart

Articles related to Common Wart:

(show top 50) (show all 554)
# Title Authors PMID Year
1
Expression of cell-cycle proteins p53, p21 (WAF-1), PCNA and Ki-67 in benign, premalignant and malignant skin lesions with implicated HPV involvement. 53 62
10429981 1999
2
PCNA expression in cutaneous keratinous neoplasms and verruca vulgaris. 53 62
1352943 1992
3
Prevalence of skin diseases and prognosis of atopic dermatitis in primary school children in populated areas of Japan from 2010 to 2019: The Asa Study in Hiroshima, Japan. 62
36120740 2022
4
Characterizing Skin Cancer in Transplant Recipients by Fitzpatrick Skin Phototype. 62
36469283 2022
5
Epidemiologic Differences and Management of Eyelid Lesions in the Pediatric Population. 62
35275778 2022
6
Efficacy and safety of date palm leaf-based ointment for treatment of cutaneous warts: A pilot clinical trial. 62
36346021 2022
7
The efficacy and safety of intralesional Candida vaccine versus topical diphencyproprobenone in immunotherapy of verruca vulgaris: A randomized comparative study. 62
36245011 2022
8
An Improved Protocol for Comprehensive Etiological Characterization of Skin Warts and Determining Causative Human Papillomavirus Types in 128 Histologically Confirmed Common Warts. 62
36298821 2022
9
Recalcitrant verruca vulgaris regression following severe SARS-CoV-2 infection. 62
35966354 2022
10
[Nail disorders in daily practice]. 62
36300431 2022
11
Annular rupioid secondary syphilis confined to the face. 62
35842215 2022
12
Falkner's needling technique for the treatment of warts: Minimum investment, maximum benefit. 62
36147396 2022
13
Changing Trends in Benign Human Papillomavirus (HPV) Related Epithelial Neoplasms of the Oral Cavity: 1995-2015. 62
35257322 2022
14
HPV-57 Verruca Vulgaris Mimicking Epidermodysplasia Verruciformis. 62
35642965 2022
15
Vaccination against human papillomavirus is not associated with resolution of verruca vulgaris in immunocompetent 9- to 21-year olds. 62
34418514 2022
16
Our experience using 1064 nm Nd:YAG in palmoplantar warts. 62
35833729 2022
17
Successful treatment of tuberculosis verrucosa cutis with fester as primary manifestation with photodynamic therapy and anti-tubercular drugs. 62
35189390 2022
18
Clinical efficacy evaluation of 595-nm pulsed dye lasers, microwave tissue coagulation, and liquid nitrogen cryotherapy in the treatment of verruca vulgaris in children. 62
35357763 2022
19
Psychosocial Burden of Verruca Vulgaris: A Cross-Sectional Survey. 62
35674752 2022
20
Verruca Vulgaris Eruption Arising in the Setting of a Tyrosine Kinase Inhibitor. 62
35855241 2022
21
Spontaneous resolution of Verruca Vulgaris in a paediatric atopic dermatitis patient treated with dupilumab. 62
35044007 2022
22
Breast horn; A rare case presentation. 62
35638062 2022
23
Comparison of Effectiveness and Safety of Immunotherapy of Warts with Intralesional Versus Subcutaneous MMR Vaccine: An Open Label Randomized, Parallel Group, Clinical Trial. 62
36092192 2022
24
Dermoscopy of inflamed seborrheic keratosis: A great mimic of malignancy. 62
34958128 2022
25
Intralesional Bleomycin Combined With Cryotherapy in the Treatment of Recalcitrant Verruca Vulgaris. 62
35133103 2022
26
Rare Report Case of Oral Verruca Vulgaris on Torus Palatinus. 62
34674196 2022
27
Intralesional injection of vitamin D in verruca vulgaris increases cathelicidin (LL37) expression; therapeutic and immunohistochemical study. 62
32237947 2022
28
Clinical presentation of verruca vulgaris in HIV. 62
35499409 2022
29
Expression Patterns of Macrophage Migration Inhibitory Factor and Its Gene Variants (MIF-173 G˃C) in Verruca Vulgaris. 62
35712358 2022
30
Impacts of COVID-19 Pandemic on Dermatology Outpatient Department at a Tertiary Hospital in Eastern China: A Pre-Post Study. 62
36426104 2022
31
Only plantar lesion of punctate palmoplantar keratoderma with a novel missense mutation in the AAGAB gene: Two Japanese familial case reports and review of reported mutations. 62
34535911 2021
32
Cutaneous Horn Revisited: A Woman With a Verruca Vulgaris-Associated Cornu Cutaneum. 62
34976525 2021
33
Topical cidofovir for benign human papillomavirus-associated skin lesions. 62
35485335 2021
34
Role of Intralesional Vitamin D3 in the Treatment of Cutaneous Warts. 62
35283599 2021
35
Safety and Efficacy of FIT039 for Verruca Vulgaris: A Placebo-Controlled, Phase I/II Randomized Controlled Trial. 62
34909725 2021
36
Does involucrin have a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study. 62
35068499 2021
37
Verruca Vulgaris Arising Within the Red Portion of a Multicolored Tattoo. 62
34735332 2021
38
Remission of verruca vulgaris following incisional punch biopsy. 62
33734465 2021
39
Verruca Vulgaris Occurring on a Tattoo: Case Report and Review of Tattoo-Associated Human Papillomavirus Infections. 62
34646630 2021
40
Cd34+ Stromal Cells/Telocytes in Normal and Pathological Skin. 62
34298962 2021
41
COVID-19 and human papillomavirus: Paradoxical immunity. 62
33626241 2021
42
Intraoral Verruca Vulgaris. 62
34137563 2021
43
Efficacy of tuberculin immunotherapy in verruca vulgaris: Our experience from single center from North-West India and review of literature. 62
33528095 2021
44
Combination of squamous cell carcinoma and basal cell carcinoma arising from a giant verruca vulgaris involving the eyelid. 62
33553803 2021
45
A systematic review of the infectious complications of colchicine and the use of colchicine to treat infections. 62
33360321 2021
46
Epithelioid Sarcoma in a Young Child: A Case Report and Literature Review. 62
33680643 2021
47
Tattoo-Associated Viral Infections: A Review. 62
34720594 2021
48
Expression and Significance of AQP3 in Cutaneous Lesions. 62
34745849 2021
49
[Fire needling stripping after local anesthesia for verruca vulgaris: a multi-center randomized controlled trial]. 62
33559445 2021
50
Verruciform Xanthoma of the Ventral Surface of the Tongue: A Rare Case Report and Literature Review. 62
33654692 2021

Variations for Common Wart

Expression for Common Wart

Search GEO for disease gene expression data for Common Wart.

Pathways for Common Wart

Pathways related to Common Wart according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.09 TP53 PCNA

GO Terms for Common Wart

Molecular functions related to Common Wart according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mechanosensitive monoatomic ion channel activity GO:0008381 8.92 TMC8 TMC6

Sources for Common Wart

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....